# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

> **NCT05052697** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 1158 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** mIRV
- **BIOLOGICAL:** bIRV AB
- **BIOLOGICAL:** qIRV
- **BIOLOGICAL:** QIV
- **BIOLOGICAL:** bIRV AA
- **BIOLOGICAL:** bIRV BB

## Key facts

- **NCT ID:** NCT05052697
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-13
- **Primary completion:** 2023-01-27
- **Final completion:** 2023-01-27
- **Target enrollment:** 1158 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05052697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05052697, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05052697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*